Serious complications are rare after TAVR, but they can be catastrophic or fatal when they do occur. The care team at Sentara Heart Hospital found that bringing in new 3D software made it much easier to plan ahead for such issues.
The introduction of a 3D pediatric transesophegeal echo probe is having a major impact on how these pediatric congenital heart patients are being treated.
The efficiency adjustment cuts introduced in the 2026 MPFS are based on assumptions many doctors believe to be false. The American Society of Nuclear Cardiology and other medical societies are pushing back.
Anders Gilberg, Senior Vice of Government Affairs at Medical Group Management Association, explains the issues that will complicate moving Medicare from fee-for-service to value-based care models in five years.
Interventional cardiology continues to evolve, driven by rapid advancements in technology. George Dangas, MD, discussed some of the specialty's biggest ongoing trends with Cardiovascular Business.
Congress temporarily extended telemedicine provisions until March amid lobby efforts by the Medical Group Management Association (MGMA) and others to make the provisions permanent.
Rakesh Gopinathannair, MD, lead author of a recent American Heart Association scientific statement on cardiac arrhythmias associated with COVID-19, reviewed the latest science associated with this important topic.
To fully leverage today's radiology IT systems, standardization is a necessity. Steve Rankin, chief strategy officer for Enlitic, explains how artificial intelligence can help.
Stephen Browning, the FDA's assistant director of hemodynamics and heart failure diagnostics, spoke with Cardiovascular Business about the agency's perspective on AI-enabled cardiovascular devices and many other topics.
Rebecca Hahn, MD, discussed key takeaways from the TRISCEND II trial for the Edwards Lifesciences Evoque TTVR valve and shared additional details related to patient selection and implanting the device.
Clyde Yancy, MD, spoke with Cardiovascular Business about how the treatment of heart failure with preserved ejection fraction (HFpEF) has evolved in recent years.
